Mayo Clinic proceedings. Innovations, quality & outcomes最新文献

{"title":"Donation After Circulatory Death Donor Prognostication: An Emerging Challenge in Heart Transplantation","authors":"","doi":"10.1016/j.mayocpiqo.2024.07.006","DOIUrl":"10.1016/j.mayocpiqo.2024.07.006","url":null,"abstract":"","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S254245482400047X/pdfft?md5=87e486c33d4cbaee72dac73d60727771&pid=1-s2.0-S254245482400047X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141954015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"10.1016/j.mayocpiqo.2024.06.003","DOIUrl":"10.1016/j.mayocpiqo.2024.06.003","url":null,"abstract":"","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000407/pdfft?md5=768b9e700a0f7d98cd4a661c8cf6ca5d&pid=1-s2.0-S2542454824000407-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141954016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving Patient Safety Through Proper Ordering and Administration of Andexanet Alfa","authors":"","doi":"10.1016/j.mayocpiqo.2024.03.003","DOIUrl":"10.1016/j.mayocpiqo.2024.03.003","url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate prescribing practices for the anti-Xa reversal agent, andexanet alfa, to identify challenges in ordering and administering this medication, and to offer recommendations to improve patient safety.</p></div><div><h3>Patients and Methods</h3><p>This retrospective study reviewed all adult patients treated with andexanet alfa (AA) at a single institution between January 1, 2018, and March 31, 2020. We identified ordering and administration benchmarks based on recommendations from previous clinical trials on AA. We then reviewed these medical records to determine compliance with these benchmarks. We also collected data related to thrombotic complications and mortality.</p></div><div><h3>Results</h3><p>Twenty-two AA dosing sets (loading and infusion dose) were given to 20 patients. Eight (36%) dosing sets met our ordering benchmarks regarding appropriate dose, time since last direct oral anticoagulants, urgency of administration, and documentation. Three (14%) dosing sets met the administrative benchmarks of being started within 30 minutes of the initial order, and 13 (59%) dosing sets had timely infusion of the infusion dose after the loading dose. No dosing set met all our administration benchmarks. There was 1 thrombotic event within 24 hours of the correct AA dose and 1 potential death related to AA.</p></div><div><h3>Conclusion</h3><p>This study highlights challenges in ordering and administering AA at our institution and brings awareness to potential similar concerns at other institutions. These challenges also identified the need for optimized order sets, a streamlined administration process, and frequent provider education to improve patient safety.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000134/pdfft?md5=0798b850a649b22639f8402e72ce6e3f&pid=1-s2.0-S2542454824000134-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141946748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"10.1016/j.mayocpiqo.2024.06.002","DOIUrl":"10.1016/j.mayocpiqo.2024.06.002","url":null,"abstract":"","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000390/pdfft?md5=ef633af538b59f7757a6b251daacb926&pid=1-s2.0-S2542454824000390-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141637506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal Imaging in Mycobacterium Chimaera Cardiovascular Infections: The Mayo Clinic Experience","authors":"Shravya Vinnakota MBBS ,&nbsp;Alex D. Tarabochia MD ,&nbsp;Nicholas Y. Tan MD, MS ,&nbsp;William R. Miranda MD ,&nbsp;Lawrence J. Sinak MD ,&nbsp;Nandan S. Anavekar MBBCh ,&nbsp;Omar Abu Saleh MD ,&nbsp;Gabor Bagameri MD ,&nbsp;Courtney E. Bennett DO","doi":"10.1016/j.mayocpiqo.2024.05.006","DOIUrl":"https://doi.org/10.1016/j.mayocpiqo.2024.05.006","url":null,"abstract":"<div><h3>Objective</h3><p>To review the salient features of multimodality cardiovascular imaging in patients with disseminated <em>Mycobacterium chimaera</em> (MC) infections after exposure to contaminated heater-cooler units during cardiopulmonary bypass.</p></div><div><h3>Patients and Methods</h3><p>Twelve patients with confirmed MC infection were retrospectively identified after a review from January 1, 2010, to April 30, 2021. The electronic medical records were examined with a focus on transthoracic echocardiography, transesophageal echocardiography, cardiac computed tomography (CT), cardiac magnetic resonance imaging, and positron emission tomography-CT.</p></div><div><h3>Results</h3><p>Three (27.3%) patients had diagnostic findings of endocarditis on transthoracic echocardiography, with most patients having nonspecific abnormalities including elevated prosthetic valve gradients or prosthetic leaflet thickening. Transesophageal echocardiography identified 4 (36.7%) patients with vegetations and 3 (27.3%) with aortic root abscess or pseudoaneurysm, with more common findings such as mild aortic root or prosthetic leaflet thickening. Six (50%) patients underwent cardiac CT imaging, which found aortic root pseudoaneurysms or abscesses, prosthetic ring dehiscence, and leaflet thickening. Three (25%) patients underwent cardiac magnetic resonance imaging demonstrating prosthetic valve vegetations, leaflet thickening, and abnormal myocardial delayed enhancement in a noncoronary distribution, suggesting myocarditis. Ten (83%) patients underwent positron emission tomography-CT, 4 (40%) had an abnormal fluorodeoxyglucose uptake around the cardiac prosthetic material, and 7 (70%) had a fluorodeoxyglucose uptake in other organs, suggesting concomitant multiorgan involvement.</p></div><div><h3>Conclusion</h3><p>Multimodality cardiovascular imaging is central to the management of patients with disseminated MC and can help establish a preliminary diagnosis while awaiting confirmatory microbiological data, potentially reducing the time to diagnosis. Imaging findings are subtle and atypical, not always meeting classically modified Duke’s criteria for infectious endocarditis. Clinicians should have a high index of suspicion for the disease and a low threshold for repeat imaging when initial testing is equivocal.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000389/pdfft?md5=e415a91f7884077294b492224abb29fa&pid=1-s2.0-S2542454824000389-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141595657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What Constitutes Adequate Control of High Blood Pressure? Current Considerations","authors":"Donald E. Casey Jr. MD, MPH, MBA ,&nbsp;Alexander J. Blood MD, MSc ,&nbsp;Stephen D. Persell MD, MPH ,&nbsp;Daniel Pohlman MD ,&nbsp;Jeff D. Williamson MD, MHS","doi":"10.1016/j.mayocpiqo.2024.06.001","DOIUrl":"https://doi.org/10.1016/j.mayocpiqo.2024.06.001","url":null,"abstract":"<div><p>An estimated 45% of adult Americans currently have high blood pressure (HBP). Effective blood pressure (BP) control is essential for preventing major adverse events from cardiovascular and other vascular-related diseases, such as chronic kidney disease, stroke and dementia. A large and growing number of medical professional societies, health care organizations, and governmental agencies have now endorsed a clinical practice guideline-based target for adequate control of HBP to a systolic BP of less than 130 mm Hg. However, adequate BP control to this goal has been recently estimated to be as low as 30%. The first and most important steps to guide effective BP control include accurate, standardized BP measurement and formal assessment of overall atherosclerotic cardiovascular disease risk. In addition to appropriate pharmacologic treatment, optimal BP management must also include multifaceted guideline-directed lifestyle modifications. High-quality evidence now supports effective uniform HBP control that is consistently achievable for most of people from diverse backgrounds. This can be accomplished through identification and prioritization of social determinants of health enabled by shared decision making that is delivered via team-based care. Such integrated approaches can have a substantial impact for simultaneously reducing several major modifiable atherosclerotic cardiovascular disease risk factors. Hence, moving the “Big Needle” of improved overall cardiovascular, kidney, and brain health of the US population must no longer be solely relegated to primary care and will require a major and coordinated reprioritization of capital and evidence-based human resource allocations by all health care stakeholder organizations.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000377/pdfft?md5=0a4bf6d7fbd90fcf31e1a47f2f7e4386&pid=1-s2.0-S2542454824000377-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141540331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Retrospective External Validation of the Cleveland Clinic Malignancy Probability Prediction Model for Indeterminate Pulmonary Nodules","authors":"Michal M. Reid MD ,&nbsp;Jack J. Amja MD ,&nbsp;Irene T. Riestra Guiance MD ,&nbsp;Rupesh R. Andani MBBS ,&nbsp;Robert A. Vierkant MS ,&nbsp;Amit Goyal MD ,&nbsp;Janani S. Reisenauer MD","doi":"10.1016/j.mayocpiqo.2024.05.005","DOIUrl":"https://doi.org/10.1016/j.mayocpiqo.2024.05.005","url":null,"abstract":"<div><h3>Objective</h3><p>To perform a retrospective, multicenter, external validation of the Cleveland Clinic malignancy probability prediction model for incidental pulmonary nodules.</p></div><div><h3>Patients and Methods</h3><p>From July 1, 2022, to May 31, 2023, we identified 296 patients who underwent tissue acquisition at Mayo Clinic (MC) (n=198) and Loyola University Medical Center (n=98) with histopathology indicating malignant (n=195) or benign (n=101). Data was collected at initial radiographic identification (point 1) and at the time of intervention (point 2). Point 3 represented the most recent data. The areas under the receiver operating characteristics were calculated for each model per time point. Calibration was evaluated by comparing the predicted and observed rates of malignancy.</p></div><div><h3>Results</h3><p>The areas under the receiver operating characteristics at time points 1, 2, and 3 for the MC model were 0.67 (95% CI, 0.61-0.74), 0.67 (95% CI, 0.58-0.77), and 0.70 (95% CI, 0.63-0.76), respectively. The Cleveland Clinic model (CCM) was 0.68 (95% CI, 0.61-0.74), 0.75 (95% CI, 0.65-0.84), and 0.72 (95% CI, 0.66-0.78), respectively. The mean ± SD estimated probability for malignant pulmonary nodules (PNs) at time points 1, 2, and 3 for the CCM was 64.2±25.9, 65.8±24.0, and 64.7±24.4, which resembled the overall proportion of malignant PNs (66%). The mean estimated probability of malignancy for the MC model at each time point was 38.3±27.4, 36.2±24.4, and 42.1±27.3, substantially lower than the observed proportion of malignancies.</p></div><div><h3>Conclusion</h3><p>The CCM found discrimination similar to its internal validation and good calibration. The CCM can be used to augment clinical and shared decision-making when evaluating high-risk PNs.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000365/pdfft?md5=92d34d2a2f83aec8732ab6a8e112463c&pid=1-s2.0-S2542454824000365-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141540330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Updates on the Diagnosis and Management of Age-Related Macular Degeneration","authors":"Nithya Boopathiraj MBBS ,&nbsp;Isabella V. Wagner BS ,&nbsp;Syril K. Dorairaj MD ,&nbsp;Darby D. Miller MD ,&nbsp;Michael W. Stewart MD","doi":"10.1016/j.mayocpiqo.2024.05.003","DOIUrl":"https://doi.org/10.1016/j.mayocpiqo.2024.05.003","url":null,"abstract":"<div><p>Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the Western world, with a higher prevalence among Europeans and North Americans than that in Africans, Hispanics, and Asians. Advanced AMD is categorized as atrophic (dry) or exudative (wet/neovascular age-related macular degeneration [nAMD]). Dry AMD is characterized by progressive geographic atrophy of the retinal pigment epithelium and outer retinal layers, whereas nAMD is characterized by new vessels that invade the subretinal and/or subretinal pigment epithelium spaces. Existing treatments delay the onset of advanced AMD and reverses vision loss for a couple of years before atrophy usually decreases central visual acuity. We searched PubMed and Medline databases from January 1, 1980, to December 1, 2023, using the following search terms: <em>macular degeneration, choroidal neovascularization, geographic atrophy, drusen, age-related maculopathy, AMD, ARMD, and anti-VEGF</em>. Relevant articles in English (or English translations) were retrieved and reviewed. Bibliographies of the identified manuscripts were also reviewed to identify relevant studies. Age-related macular degeneration most commonly affects people older than 55 years. Visual prognosis varies, with advanced lesions (nAMD and geographic atrophy) leading to rapid, progressive loss of central vision and contrast sensitivity. Although AMD is not a life-threatening disease, reduced vision profoundly compromises quality of life and necessitates living assistance for many patients. Over the past 2 decades, advances in prevention (vitamin supplementation) and therapy (antivascular endothelial growth factor and complement inhibitor drugs) have reduced vision loss and blindness. Further research is needed to decrease the incidence of blindness in patients with advanced disease.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000316/pdfft?md5=75444bd2f23f87ca21d619f7ce1db676&pid=1-s2.0-S2542454824000316-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141485068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Committed to Success: A Structured Mentoring Program for Clinically Oriented Physicians","authors":"Nathan Houchens MD ,&nbsp;Latoya Kuhn MPH ,&nbsp;David Ratz MS ,&nbsp;Grace L. Su MD ,&nbsp;Sanjay Saint MD, MPH","doi":"10.1016/j.mayocpiqo.2024.05.002","DOIUrl":"https://doi.org/10.1016/j.mayocpiqo.2024.05.002","url":null,"abstract":"<div><h3>Objective</h3><p>To examine impacts of a structured mentorship committee program on academic promotion and participant perceptions because impacts of formal mentorship programs for clinical faculty are unknown.</p></div><div><h3>Participants and Methods</h3><p>This prospective cohort study at a Midwestern Veterans Affairs tertiary care system from December 17, 2019 to December 31, 2022 included clinical track faculty in the Medicine Service below the rank of Clinical Associate Professor. Mentoring meetings (mentee, committee chair, and mentors) were generally held twice annually. All participants were surveyed after each meeting (response rate: 100%).</p></div><div><h3>Results</h3><p>All 23 of 23 (100%) eligible faculty were enrolled as mentees, and 49 distinct meetings occurred. Three (13%) mentees were promoted, and the remaining 20 (87%) continued in the program. Mean scores (SD), scaled 1 (strongly disagree) to 5 (strongly agree), for mentors and mentees were 4.71 (0.51) and 4.80 (0.54) for “effective use of my time”; 4.58 (0.64) and 4.37 (0.49) for “appropriate progress since last meeting”; 4.52 (0.66) and 4.31 (0.64) for “program increased my work satisfaction”; and 4.07 (0.96) and 3.75 (0.92) for “program reduced my work burnout,” respectively.</p></div><div><h3>Conclusion</h3><p>Clinically oriented physicians viewed the program positively. It appeared to help junior faculty get promoted and led to improved work satisfaction and reduced burnout.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000304/pdfft?md5=1633d9e06205fb7b260a3b65ddf925ab&pid=1-s2.0-S2542454824000304-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141324855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Left Atrial Function With Incident Chronic Kidney Disease in Older Adults","authors":"Wendy Wang PhD, MPH ,&nbsp;Jorge L. Reyes MD, MS ,&nbsp;Abayomi Oyenuga MD, MPH ,&nbsp;Anne A. Eaton PhD, MS ,&nbsp;Faye L. Norby PhD, MPH ,&nbsp;Romil Parikh MBBS, MPH ,&nbsp;Riccardo M. Inciardi MD ,&nbsp;Alvaro Alonso MD, PhD ,&nbsp;Pamela L. Lutsey PhD, MPH ,&nbsp;Charles A. Herzog MD ,&nbsp;Junichi Ishigami MD, PhD ,&nbsp;Kunihiro Matsushita MD, PhD ,&nbsp;Josef Coresh MD, PhD ,&nbsp;Amil M. Shah MD ,&nbsp;Scott D. Solomon MD ,&nbsp;Lin Yee Chen MD, MS","doi":"10.1016/j.mayocpiqo.2024.05.001","DOIUrl":"https://doi.org/10.1016/j.mayocpiqo.2024.05.001","url":null,"abstract":"<div><h3>Objective</h3><p>To examine the association of left atrial (LA) function with incident chronic kidney disease (CKD) and assess the clinical utility of adding LA function to a CKD risk prediction equation.</p></div><div><h3>Patients and Methods</h3><p>We included 4002 Atherosclerosis Risk in Communities study participants without prevalent CKD (mean ± SD age, 75±5 years; 58% female, 18% Black). Left atrial function (reservoir, conduit, and contractile strain) was evaluated by 2D-echocardiograms on 2011 to 2013. Chronic kidney disease was defined as greater than 25% decline in estimated glomerular filtration rate of less than 60 mL/min/1.73 m², end-stage kidney disease, or hospital records. Cox proportional hazards models were used. Risk prediction and decision curve analyses evaluated 5-year CKD risk by diabetes status.</p></div><div><h3>Results</h3><p>Median follow-up was 7.2 years, and 598 participants developed incident CKD. Incidence rate for CKD was 2.29 per 100 person-years. After multivariable adjustments, the lowest quintile of LA reservoir, conduit, and contractile strain (vs highest quintile) had a higher risk of CKD (hazard ratios [95% CIs]: 1.94 [1.42-2.64], 1.62 [1.19-2.20], and 1.49 [1.12-1.99]). Adding LA reservoir strain to the CKD risk prediction equation variables increased the C-index by 0.026 (95% CI: 0.005-0.051) and 0.031 (95% CI: 0.006-0.058) in participants without and with diabetes, respectively. Decision curve analysis found the model with LA reservoir strain had a higher net benefit than the model with CKD risk prediction equation variables alone.</p></div><div><h3>Conclusion</h3><p>Lower LA function is independently associated with incident CKD. Adding LA function to the CKD risk prediction enhances prediction and yields a higher clinical net benefit. These findings suggest that impaired LA function may be a novel risk factor for CKD.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000298/pdfft?md5=8e701f269a9730594907e4d33ad431a2&pid=1-s2.0-S2542454824000298-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141313537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}